Core Insights - The Company is assessing U.S. licensing pathways for its Canna Cabana retail brand and is evaluating Medicare-aligned product categories for its CBD brands, NuLeaf Naturals and FAB CBD [1][3] Group 1: Regulatory Developments - The Executive Order from the White House is a significant step in U.S. federal cannabis reform, indicating bipartisan support for cannabis and CBD policy changes [2] - The Centers for Medicare & Medicaid Services is expected to launch a pilot program allowing certain Medicare beneficiaries to receive CBD treatments at no cost, which could enhance market opportunities for the Company [1][2] Group 2: Business Strategy - The Company is exploring the feasibility of expanding Canna Cabana into the U.S. through a licensing model while ensuring compliance with NASDAQ and TSXV listings [3] - NuLeaf Naturals and FAB CBD are developing Medicare-aligned product categories to potentially be included in Medicare Advantage supplemental benefits, leveraging their CGMP-certified operations and large customer base [3] Group 3: Market Position - High Tide operates the largest cannabis retail chain in Canada, with 218 domestic and 1 international location, holding a 12% market share [6] - The Company has been recognized as one of Canada's Top Growing Companies and ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023 [8]

Core Insights - The recent executive order formalizing cannabis reclassification has sparked significant discussion regarding policy and capital implications, while operational aspects have received less focus [1] Group 1: Policy Implications - The reclassification of cannabis is expected to influence regulatory frameworks and investment strategies within the industry [1] Group 2: Capital Market Impact - The executive order may lead to increased capital flow into the cannabis sector as investors reassess the risk and opportunity landscape [1] Group 3: Operational Considerations - There is a noted lack of attention on how the reclassification will affect operational practices within cannabis companies [1]

Industry Overview - The marijuana industry is currently experiencing volatility, with potential changes in legislation under the Trump administration that may lead to the reclassification of marijuana for therapeutic use [2][3] - The cannabis sector is described as "the wild west," characterized by a lack of standardization and a diverse range of products from various suppliers, making it challenging for companies to achieve steady revenue growth [5][6] Company Insights - Company Tillray operates in the marijuana space, including CBD oils and beverages, and is noted as the fourth largest craft brew company in the U.S. [3] - Despite the potential for short-term opportunities due to legislative changes, Tillray faces significant challenges in standardizing its products and maintaining profitability [5][6] - Tillray's sales were approximately $830 million last year, with growth in the mid-single digits, but the company reported a loss of around $2 billion, which continues to pressure its equity [8] Market Dynamics - The cannabis ETF has seen a decline of over 85% from its peak, indicating a loss of enthusiasm in the market despite positive headlines regarding legalization [6] - Positive news in the marijuana sector often leads to short-term price increases, but these gains are not sustainable due to the industry's profitability challenges [7]

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs†or the "Company†), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump's action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act. "Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, ackn. ...

Verano’s active operations span 13 states, comprised of 158 dispensaries operating under the Zen Leaf™ and MÜV™ retail banners, and 15 cultivation and processing facilities with more than 1.1 million square feet of cultivation capacity CHICAGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, celebrates today’s historic announcement that President Donald Trump has issued an Executive Order directing the ...

Core Viewpoint - The reclassification of marijuana to Schedule III under the Controlled Substances Act is a significant step towards cannabis reform, facilitating medical research and alleviating the tax burden on legal cannabis operators [1][2]. Group 1: Impact on Research - Reclassifying marijuana to Schedule III acknowledges its medical benefits and reduces restrictions on conducting medical research in the U.S., allowing American companies and universities to lead in research on medical applications and appropriate dosages for various patient populations [3]. Group 2: Tax Implications - The removal of the punitive tax burden imposed by Section 280E of the tax code supports state-licensed cannabis operators by allowing them to deduct ordinary business expenses, which was previously not possible due to the classification of marijuana as a Schedule I substance [4]. Group 3: Law Enforcement and Illegal Operations - The reclassification aligns with a broader commitment to differentiate between legal cannabis operators and illegal drug traffickers, enabling law enforcement to effectively target illicit operators while maintaining the authority to prosecute those selling marijuana to minors [5]. Group 4: Company Overview - Trulieve Cannabis Corp. is a leading vertically integrated cannabis company in the U.S., with strong market positions in Arizona, Florida, and Pennsylvania, and is focused on growth and expansion through innovative product offerings and a hub strategy [6].

Core Viewpoint - The executive order signed by President Trump represents a significant shift in U.S. cannabis policy, reclassifying marijuana from Schedule I to Schedule III, which could have major implications for the cannabis industry and its financial landscape [1][2]. Industry Impact - The reclassification is seen as a financial lifeline for the cannabis industry, allowing companies to deduct standard expenses like rent and payroll for the first time due to exemption from IRS Code Section 280E [6]. - The move is expected to facilitate banking access and attract institutional capital that has previously been deterred by compliance concerns [6]. - Analysts anticipate that the changes, along with the Medicare pilot program, may draw major pharmaceutical companies into the cannabis sector to pursue federally insured revenue [6]. Market Reaction - Following the announcement, shares of cannabis companies showed mixed results: Tilray Brands increased by approximately 6%, while Trulieve and Green Thumb Industries saw declines of about 15% and 5%, respectively. The AdvisorShares Pure US Cannabis ETF fell by more than 10% [5]. Regulatory Developments - The Centers for Medicare and Medicaid Services is set to launch a pilot program allowing certain Medicare-covered seniors to receive free, doctor-recommended CBD products, which must comply with local and state laws [4]. - The executive order does not legalize marijuana for recreational use, but it may encourage further research into the effects of CBD [8]. Consumer Trends - CBD has gained popularity in various consumer goods, but the FDA has not fully endorsed the compound, citing inconsistent benefits and potential risks associated with prolonged use [7].

Core Viewpoint - The reclassification of cannabis as a Schedule III drug by the Trump Administration is a significant reform that acknowledges its medical uses and low abuse potential, which will have long-term benefits for the cannabis industry [2]. Group 1: Impact of Reclassification - The reclassification is expected to accelerate accredited medical research into cannabis-derived medications, leading to increased consumer acceptance of cannabis as an alternative to opioids for chronic pain, sleep, anxiety, and other ailments [3]. - State-legal cannabis businesses will benefit from the removal of the IRS Section 280E tax penalty, allowing compliant operators like MariMed to be taxed similarly to other consumer packaged goods sectors, which will enhance profitability and free cash flow [4]. Group 2: Company Overview - MariMed Inc. is recognized as a leading multi-state cannabis operator, specializing in the development and management of advanced cultivation, production, and retail facilities [4]. - The company boasts an award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby's Baked™, Vibations™, InHouse™, and Nature's Heritage™, which are well-regarded by consumers nationwide [4].

Shares of Tilray Brands and other cannabis stocks are rising ahead of President Donald Trump's executive order signing ceremony. ...

Core Viewpoint - Tilray and Canopy Growth shares experienced significant gains on Thursday, indicating positive market sentiment towards these companies in the cannabis industry [1] Company Summary - Tilray's stock performance showed notable improvement, contributing to its position as a leading player in the cannabis market [1] - Canopy Growth also reported substantial gains, reflecting investor confidence and potential growth opportunities within the company [1] Industry Summary - The cannabis industry is witnessing a positive trend, with key players like Tilray and Canopy Growth leading the charge in market performance [1] - The overall market sentiment appears to be shifting favorably towards cannabis stocks, suggesting a potential recovery or growth phase for the industry [1]